16-fluoro-5-androsten-17-one has been researched along with Cancer of Skin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alberts, DS; Boone, CW; Covey, JM; Crowell, JA; Doody, LA; Greenwald, P; Kelloff, GJ; Knapp, GG; Lubet, RA; Steele, VE | 1 |
| Lewbart, ML; Pashko, LL; Schwartz, AG | 1 |
2 other study(ies) available for 16-fluoro-5-androsten-17-one and Cancer of Skin
| Article | Year |
|---|---|
Clinical development plan: DHEA analog 8354.
Topics: Androstenes; Animals; Antineoplastic Agents; Clinical Trials as Topic; Dogs; Drug Approval; Female; Humans; Male; Mice; Rats; Rats, Sprague-Dawley; Skin Neoplasms | 1994 |
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-promoted skin tumor formation in mice by 16 alpha-fluoro-5-androsten-17-one and its reversal by deoxyribonucleosides.
Topics: Androstenes; Animals; Body Weight; Deoxyribonucleosides; Drug Interactions; Female; Mice; Mice, Inbred Strains; Papilloma; Skin Neoplasms; Tetradecanoylphorbol Acetate | 1991 |